Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?
Adjuvant hormone therapy
Aromatase inhibitor
Early breast cancer
ICIQ-UI SF
Tamoxifen
Urinary Incontinence
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
10 May 2023
10 May 2023
Historique:
received:
10
11
2022
accepted:
01
05
2023
medline:
12
5
2023
pubmed:
10
5
2023
entrez:
10
5
2023
Statut:
epublish
Résumé
The primary aim of this study was to compare tamoxifen versus aromatase inhibitors (AI) in terms of urinary incontinence (UI) in premenopausal female patients receiving adjuvant hormone therapy for breast cancer. A secondary aim was to investigate the prevalence and the affecting factors of UI. This study was designed as a multicenter, cross-sectional that included consecutive premenopausal breast cancer patients ≤50 years of age receiving tamoxifen (with/without LHRHa) or AI (with LHRHa) for at least 6 months, between June 2021 and September 2022. Patients with urinary incontinence before hormone treatments and metastatic patients were excluded from the study. Turkish validation of The International Consultation on Incontinence Modular Questionnaire Urinary Incontinence Short Form (ICIQ UI-SF) was used to determine the UI. Using logistic regression methods, we analyzed potential predictive factors for UI. A total of 206 breast cancer patients were included in this study. A total of 120 (58.2%) patients were receiving tamoxifen plus LHRHa, 40 (19.4%) patients were receiving aromatase inhibitor plus LHRHa, and 46 (22.3%) patients were receiving tamoxifen only. In this study, the prevalence of urinary incontinence was found to be 35.9% (n:74). 41% of the patients receiving tamoxifen and 15.0% of those receiving aromatase inhibitors had complaints of urinary incontinence. There was a statistically significant difference between patients receiving tamoxifen or aromatase inhibitor in terms of urinary incontinence (p=0.001). In the univariate analysis established to predict UI, parity (≥2 vs <2) (OR = 3.23, 95% CI: 1.62-6.46, p= 0.001), tamoxifen (vs AI) (OR = 3.97, 95% CI: 1.58-9.98, p= 0.003), age ( ≥40 vs. <40) (OR = 2.80, 95% CI: 1.37-5.71, p= 0.005), vaginal deliveries (≥2 vs. <2) (OR = 3.28, 95% CI: 1.44-7.46, p= 0.005), hypertension (OR = 3.59, 95% CI: 1.43-9.02, p= 0.007), diuretic use (OR = 2.55, 95% CI: 1.09-5.95, p= 0.031) ), and body mass index (≥25 vs <25) (OR = 1.94, 95% CI: 1.05-3.63), p= 0.034) was found to be predictive. Tamoxifen (OR = 4.71, 95% CI: 1.77-12.56, p= 0.002), hypertension (OR = 3.48, 95% CI: 1.27-9.52, p= 0.015), and age (OR = 2.35, 95% CI: 1.10-5.02, p= 0.027) remained independent predictors for incontinence in multivariate analyses. We found that tamoxifen had increased the risk of urinary incontinence compared to aromatase inhibitors in patients receiving hormone therapy for breast cancer. In addition, we showed that age and hypertension were also independent predictors for UI. In the context of quality of life, we recommend close follow-up of these patients, as drug adherence may be affected in the event of urinary incontinence.
Identifiants
pubmed: 37162602
doi: 10.1007/s00520-023-07791-7
pii: 10.1007/s00520-023-07791-7
doi:
Substances chimiques
Adjuvants, Pharmaceutic
0
Aromatase Inhibitors
0
Hormones
0
Tamoxifen
094ZI81Y45
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
330Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Siegel RL et al (2021) Cancer Statistics, 2021. CA Cancer J Clin 71(1):7–33. https://doi.org/10.3322/caac.21654
doi: 10.3322/caac.21654
pubmed: 33433946
National Cancer Institute. Cancer stat facts: female breast cancer. https://seer.cancer.gov/statfacts/html/breast.html . Accessed May 16, 2021.
(2008) Stat bite: Cancer survivors in the United States. J Natl Cancer Inst 100(4):236. https://doi.org/10.1093/jnci/djn018
Arndt V, Merx H, Stegmaier C, Ziegler H, Brenner H (2005) Persistence of restrictions in quality of life from the first to the third year after diagnosis in women with breast cancer. J Clin Oncol 23(22):4945–4953. https://doi.org/10.1200/JCO.2005.03.475
doi: 10.1200/JCO.2005.03.475
pubmed: 16051947
Cavdar E, Iriagac Y, Karaboyun K, Avci O, Seber E (2021) Understanding breast cancer from the patients’ perspective. EJMI 5(3):322–328
Fisher B et al (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86(7):527–537. https://doi.org/10.1093/jnci/86.7.527
doi: 10.1093/jnci/86.7.527
pubmed: 8133536
Chalas E, Costantino JP, Wickerham DL et al (2005) Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Am J Obstet Gynecol 192(4):1230–1239. https://doi.org/10.1016/j.ajog.2004.12.083
doi: 10.1016/j.ajog.2004.12.083
pubmed: 15846210
Diel P (2002) Tissue-specific estrogenic response and molecular mechanisms. Toxicol Lett 127(1-3):217–224. https://doi.org/10.1016/s0378-4274(01)00503-3
doi: 10.1016/s0378-4274(01)00503-3
pubmed: 12052661
Fallowfield LJ et al (1999) Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat 55(2):189–199. https://doi.org/10.1023/a:1006263818115
doi: 10.1023/a:1006263818115
pubmed: 10481946
Schmidt M et al (2021) Tumor suppression, dose-limiting toxicity and wellbeing with the fetal estrogen estetrol in patients with advanced breast cancer. J Cancer Res Clin Oncol 147(6):1833–1842. https://doi.org/10.1007/s00432-020-03472-8
doi: 10.1007/s00432-020-03472-8
pubmed: 33242131
Stahlschmidt R et al (2019) Adherence and quality of life in women with breast cancer being treated with oral hormone therapy. Support Care Cancer 27(10):3799–3804. https://doi.org/10.1007/s00520-019-04671-x
doi: 10.1007/s00520-019-04671-x
pubmed: 30729297
Hershman DL et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529–537. https://doi.org/10.1007/s10549-010-1132-4
doi: 10.1007/s10549-010-1132-4
pubmed: 20803066
Sella T, Chodick G (2020) Adherence and persistence to adjuvant hormonal therapy in early-stage breast cancer patients: a population-based retrospective cohort study in Israel. Breast Care (Basel, Switzerland) 15(1):45–53. https://doi.org/10.1159/000500318
doi: 10.1159/000500318
pubmed: 32231497
Nekhlyudov L et al (2011) Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat 130(2):681–689. https://doi.org/10.1007/s10549-011-1703-z
doi: 10.1007/s10549-011-1703-z
pubmed: 21842245
Cahir C et al (2015) Women’s experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour. Support Care Cancer 23(11):3115–3130. https://doi.org/10.1007/s00520-015-2685-x
doi: 10.1007/s00520-015-2685-x
pubmed: 25744290
Vardy MD et al (2003) Short-term urogenital effects of raloxifene, tamoxifen, and estrogen. Am J Obstet Gynecol 189(1):81–88. https://doi.org/10.1067/mob.2003.374
doi: 10.1067/mob.2003.374
pubmed: 12861143
Cardozo L et al (1998) Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 92(4 Pt 2):722–727. https://doi.org/10.1016/s0029-7844(98)00175-6
doi: 10.1016/s0029-7844(98)00175-6
pubmed: 9764689
Hasanov E, Hasanov M, Kuria IM, Hasanov R, Rzazade R, Jonasch E, Altundag K (2017 Aug) Effects of tamoxifen on urinary incontinence: case report and review of literature. Medicine (Baltimore) 96(34):e6785. https://doi.org/10.1097/MD.0000000000006785
doi: 10.1097/MD.0000000000006785
pubmed: 28834864
Cook ED et al (2017) Missing documentation in breast cancer survivors: genitourinary syndrome of menopause. Menopause 24(12):1360–1364. https://doi.org/10.1097/GME.0000000000000926
doi: 10.1097/GME.0000000000000926
pubmed: 28640166
pmcid: 5709152
Eriguchi T et al (2018) High luteinizing hormone weakens urinary continence mechanisms in association with prostaglandin E2 elevation in a postmenopausal rat model. Neurourol Urodyn 37(4):1294–1301. https://doi.org/10.1002/nau.23470
doi: 10.1002/nau.23470
pubmed: 29315797
Droupy S, Colson MH, Pello‐Leprince‐Ringuet N, Perrot V, Descazeaud A. EQUINOXE study: Impact of relational cohesion and sexuality on the quality of life of patients treated with gonadotropin‐releasing hormone agonist for prostate cancer. BJUI Compass 2022;3(1):45-54.
Avery K, Donovan J, Peters TJ et al (2004) ICIQ: A brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn 23:322–330
doi: 10.1002/nau.20041
pubmed: 15227649
Johansson A et al (2022) Twenty-year benefit from adjuvant goserelin and tamoxifen in premenopausal patients with breast cancer in a controlled randomized clinical trial. J Clin Oncol 40(35):4071–4082. https://doi.org/10.1200/JCO.21.02844
doi: 10.1200/JCO.21.02844
pubmed: 35862873
Gremke N et al (2022) Persistence with tamoxifen and aromatase inhibitors in Germany: a retrospective cohort study with 284,383 patients. J Cancer Res Clin Oncol. https://doi.org/10.1007/s00432-022-04376-5
Francis PA et al (2018) Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 379(2):122–137. https://doi.org/10.1056/NEJMoa1803164
doi: 10.1056/NEJMoa1803164
pubmed: 29863451
pmcid: 6193457
Chung CP et al (2020) Serial assessment of urinary incontinence in breast cancer survivors undergoing (neo)adjuvant therapy. Journal of the National Comprehensive Cancer Network : JNCCN 18(6):712–716. https://doi.org/10.6004/jnccn.2020.7535
Imamoglu GI et al (2019) Is tamoxifen use a factor affecting continence in breast cancer patients? Cureus 11:8
Stahlschmidt R et al (2020) Urinary incontinence and overactive bladder symptoms in women with breast cancer being treated with oral hormone therapy. Revista Brasileira de Ginecologia e Obstetricia 42(11):726–730. https://doi.org/10.1055/s-0040-1718440
doi: 10.1055/s-0040-1718440
pubmed: 33254267
Kuiper GG, et al (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 138(3):863–70. https://doi.org/10.1210/endo.138.3.4979
George SK, Tovar-Sepulveda V, Shen SS, Jian W, Zhang Y, Hilsenbeck SG et al (2013) Chemoprevention of BBN-induced bladder carcinogenesis by the selective estrogen receptor modulator tamoxifen. Transl Oncol 6(3):244–255
doi: 10.1593/tlo.13247
pubmed: 23730403
pmcid: 3660792
Tanaka ST, Ishii K, Demarco RT, Pope JC, Brock JW, Hayward SW (2010) Endodermal origin of bladder trigone inferred from mesenchymal-epithelial interaction. J Urol 183(1):386–391
doi: 10.1016/j.juro.2009.08.107
pubmed: 19914648
pmcid: 2794964
Clark AL, Slayden OD, Hettrich K, Brenner RM (2005) Östrojen, rhesus makakının pelvik destek dokularında kollajen I ve III mRNA ekspresyonunu arttırır. Ben. J Obstet Gynecol 192(5):1523–1529. https://doi.org/10.1016/j.ajog.2004.11.042
doi: 10.1016/j.ajog.2004.11.042
Hannestad YS et al (2003) Are smoking and other lifestyle factors associated with female urinary incontinence? The Norwegian EPINCONT Study. BJOG 110(3):247–254
doi: 10.1046/j.1471-0528.2003.02327.x
pubmed: 12628262
Danforth KN et al (2006) Risk factors for urinary incontinence among middle-aged women. Am J Obstet Gynecol 194(2):339–345. https://doi.org/10.1016/j.ajog.2005.07.051)
doi: 10.1016/j.ajog.2005.07.051)
pubmed: 16458626
pmcid: 1363686
Padmanabhan P, Dmochowski R (2014) Urinary incontinence in women: a comprehensive review of the pathophysiology, diagnosis and treatment. Minerva Ginecol 66(5):469–478
pubmed: 25078140
Tevaarwerk AJ et al (2014) Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 32(35):3948–3958. https://doi.org/10.1200/JCO.2014.55.6993
doi: 10.1200/JCO.2014.55.6993
pubmed: 25349302
pmcid: 4251958